United TherapeuticsUTHR
About: United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Employees: 1,305
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
129% more first-time investments, than exits
New positions opened: 103 | Existing positions closed: 45
28% more repeat investments, than reductions
Existing positions increased: 264 | Existing positions reduced: 207
21% more call options, than puts
Call options by funds: $46M | Put options by funds: $37.9M
7% more funds holding
Funds holding: 616 [Q3] → 662 (+46) [Q4]
1.33% more ownership
Funds ownership: 97.03% [Q3] → 98.36% (+1.33%) [Q4]
0% more capital invested
Capital invested by funds: $15.4B [Q3] → $15.5B (+$55.1M) [Q4]
29% less funds holding in top 10
Funds holding in top 10: 17 [Q3] → 12 (-5) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Andrew Fein 27% 1-year accuracy 95 / 352 met price target | 49%upside $425 | Buy Reiterated | 27 Feb 2025 |
Financial journalist opinion
Based on 5 articles about UTHR published over the past 30 days
